8-K: Septerna Reports Strong Q3, Advances Pipeline, Extends Runway

Septerna, Inc. announced robust third-quarter 2025 financial results, significant pipeline progress, and an extended cash runway into at least 2029.

Summary

• Septerna reported a net income of $8.2 million for Q3 2025, a significant improvement from a net loss of $20.5 million in Q3 2024.
• Revenue for Q3 2025 surged to $21.5 million, up from $0.2 million in Q3 2024, driven by the Novo Nordisk collaboration and a Vertex milestone payment.
• Cash, cash equivalents, and marketable securities totaled $561.6 million as of September 30, 2025, providing a cash runway expected to fund operations into at least 2029.
• SEP-479, an oral PTH1R agonist for hypoparathyroidism, was selected as a next-generation development candidate, with a Phase 1 clinical trial planned for the first half of 2026.
• A Phase 1 clinical trial for SEP-631, an oral MRGPRX2 NAM for mast cell diseases, is ongoing in healthy volunteers, with initial data expected in the first half of 2026.
• The global collaboration and license agreement with Novo Nordisk formally commenced in July, with joint research and development activities underway for cardiometabolic diseases.
• Keith Gottesdiener, M.D., was appointed to the Board of Directors in September and will chair the newly formed R&D Committee.

Sentiment

Score: 9

Explanation: The filing indicates strong positive momentum with a significant financial turnaround to net income, substantial revenue growth from strategic collaborations, a robust cash position extending the runway for several years, and clear advancement of key pipeline programs with upcoming milestones. The appointment of a new R&D committee chair further strengthens the company's strategic capabilities.

Positives

• Achieved net income of $8.2 million in Q3 2025, a substantial turnaround from a $20.5 million net loss in Q3 2024.
• Revenue increased significantly to $21.5 million in Q3 2025 from $0.2 million in Q3 2024, primarily due to the Novo Nordisk collaboration and Vertex milestone.
• Strong cash position of $561.6 million as of September 30, 2025, extending the cash runway into at least 2029.
• Selection of SEP-479 as a next-generation oral PTH1R agonist development candidate for hypoparathyroidism, demonstrating robust preclinical results.
• Initiation of a Phase 1 clinical trial for SEP-631 for mast cell diseases, with initial data anticipated in the first half of 2026.
• Formal commencement of the global collaboration with Novo Nordisk, validating Septerna's Native Complex Platform and providing significant upfront funding.
• Appointment of Dr. Keith Gottesdiener to the Board of Directors and as chairperson of the R&D Committee, strengthening scientific and strategic leadership.

Risks

• Product candidates may not successfully enter or advance through clinical trials, including SEP-479 and SEP-631.
• Uncertainties exist regarding the authorization, initiation, and successful completion of preclinical and Investigational New Drug (IND)-enabling studies to support future clinical development.
• Clinical development outcomes may include unexpected safety or efficacy findings.
• Results from preclinical studies or early clinical studies may not be predictive of future clinical outcomes.
• Risks related to the timing of initiating clinical studies and the future availability of clinical data.
• Challenges in establishing and maintaining intellectual property rights covering the Native Complex Platform and product candidates.
• Ability to maintain existing collaborations, identify and enter into future license agreements, and realize their intended benefits.
• Unanticipated future expense levels and capital requirements could impact financial stability.
• General economic, industry, and market conditions may adversely affect business operations and financial performance.

Future Outlook

Septerna anticipates initiating a Phase 1 clinical trial for SEP-479 in the first half of 2026, subject to successful completion of preclinical activities and regulatory submissions. Initial single-ascending-dose and multiple-ascending-dose data from the SEP-631 Phase 1 clinical trial are expected in the first half of 2026. The company continues to advance its TSHR NAM program towards development candidate selection and expects its existing cash runway to fund operations into at least 2029.

Management Comments

• "In the third quarter, we made meaningful progress across our portfolio, highlighted by the selection of SEP-479 as our next-generation PTH1R agonist development candidate for hypoparathyroidism and the initiation of our Phase 1 clinical trial for SEP-631 which targets MRGPRX2 for mast cell-driven diseases."
• "Both programs exemplify the power of our Native Complex Platform to generate differentiated oral small-molecule GPCR therapies with the potential to address serious diseases across a range of indications."
• "With multiple milestones anticipated in the first half of 2026, we are executing with focus and momentum as we work to deliver meaningful therapies for patients."

Industry Context

Septerna operates in the highly competitive biotechnology sector, specifically focusing on G protein-coupled receptor (GPCR) drug discovery, a historically challenging but high-potential area. The company's Native Complex Platform aims to differentiate its oral small-molecule therapies. Its collaboration with Novo Nordisk for cardiometabolic diseases aligns with a broader industry trend of large pharmaceutical companies partnering with innovative biotechs to access novel platforms and expand pipelines in high-demand therapeutic areas like obesity and type 2 diabetes.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, extended cash runway, and significant pipeline advancements, potentially leading to increased share value.
• Patients: Potential for new, differentiated oral small-molecule therapies for serious diseases like hypoparathyroidism, mast cell diseases, Graves disease, thyroid eye disease, obesity, and type 2 diabetes.
• Employees: Stable employment and continued R&D opportunities due to robust financial health and pipeline progress.
• Partners (Novo Nordisk, Vertex): Successful collaboration and milestone achievements reinforce the value of partnerships and Septerna's platform.

Next Steps

• Complete remaining preclinical development activities for SEP-479.
• Initiate a Phase 1 clinical trial for SEP-479 in the first half of 2026.
• Continue the Phase 1 clinical trial for SEP-631 in healthy volunteers.
• Expect initial single-ascending-dose and multiple-ascending-dose data for SEP-631 in the first half of 2026.
• Continue progress toward the selection of a development candidate for the TSHR NAM program.
• Continue to advance discovery-stage programs utilizing the Native Complex Platform.
• Continue joint research and development activities with Novo Nordisk for cardiometabolic diseases.

Key Dates

Recommendation

Septerna's Q3 2025 results demonstrate a significant positive inflection point, marked by a shift to net income, substantial revenue growth from strategic collaborations, and a robust cash position that extends its operational runway into at least 2029. The advancement of key pipeline assets (SEP-479 and SEP-631) with clear near-term milestones, coupled with the validation from the Novo Nordisk partnership and strengthened corporate governance, signals strong operational execution and future growth potential. These factors collectively present a compelling investment case for long-term value creation.

Keywords

Septerna, SEPN, biotechnology, GPCR, drug discovery, clinical-stage, Q3 2025 earnings, financial results, pipeline update, SEP-479, hypoparathyroidism, PTH1R agonist, SEP-631, mast cell diseases, MRGPRX2 NAM, Novo Nordisk collaboration, cash runway, R&D, Native Complex Platform, TSHR NAM, Graves disease, thyroid eye disease